Group 1: Report Overview - Report title: Coal and Coke Weekly View [1] - Date: October 12, 2025 [2] - Analyst: Zhang Guangshuo [2] Group 2: Investment Rating - Not provided Group 3: Core Viewpoints - Coal and coke may continue weak and volatile due to repeated macro - expectations [3] - After pre - holiday restocking, post - holiday demand is weak and trading atmosphere is cold [4] - The fundamentals of coal and coke show a situation of weak supply and demand, with relatively small marginal contradictions, and the current disk valuation may be dominated by macro factors [5] Group 4: Coal and Coke Fundamentals Data Supply - For coal, FW raw coal is 836.67 (- 39.93), FW clean coal is 426.31 (- 25.64); for coke, independent coking plants' daily average is 66.12 (+ 0.04), and steel mills' coking plants' daily average is 46.38 (- 0.16) [7] Demand - Iron and steel water production is 241.54 (- 0.27) for both coal and coke [7] Inventory - MS total inventory for coal is - 78.8, with various changes in different sectors; for coke, MS total inventory is - 10.1, independent coking + 1.5 [7] Profit - Commodity coal profit is 466 (+ 14), and coking enterprises' average profit is 9 (+ 45) [7] Warehouse Receipt - Mongolian 5 Tangshan warehouse receipt is 1176, and Rizhao standard first - grade coke warehouse receipt is 1568 [7] Group 5: Coking Coal Fundamental Data Supply - Weekly and monthly production data are presented in multiple charts, including 523 sample mine production rates, FW raw coal and clean coal production, and Mongolian coal customs clearance volume [10][14][16] Inventory - Pit - mouth inventory: This week, sample mine raw coal inventory increased by 2.72 tons to 165.05 tons, and clean coal inventory increased by 6.48 tons to 111.16 tons [27] - Port inventory: This week, coking coal port inventory is 294.99 tons, a week - on - week increase of 12.8 tons [29] - Coking plant inventory: Data on inventory and available days are presented in different regions and production capacities [32][34][36] - Steel mill inventory: Data on inventory and available days are presented for 247 steel enterprises and in different regions [37] Group 6: Coke Fundamental Data Supply - Capacity utilization: Data of independent coking enterprises and steel mills are presented, including different production capacity levels and regions [40][42] - Production: Data of independent coking enterprises and steel mills are presented, including daily average production [44][46] Inventory - Coking plant inventory: Data of full - sample and 230 independent coking plants are presented [48] - Steel mill inventory: Data on inventory, available days, and regional breakdown are presented [49][51][52] - Total inventory: Coke total inventory data are presented [54] Demand - Iron production data are provided, and the supply - demand difference is analyzed [56][57] Profit - Coke profit data, including disk profit and average profit of independent coking enterprises, are presented [58][59][60] Group 7: Coal and Coke Futures and Spot Prices Futures - Coking coal futures: Data of 2601 and 2605 contracts, including closing price, change, trading volume, and open interest, are presented [63] - Coke futures: Data of 2601 and 2605 contracts, including closing price, change, trading volume, and open interest, are presented [65] Month - spread - Month - spread data of JM2601 - JM2605 and J2601 - J2605 are presented [68] Spot - Spot price data of coking coal and coke are presented [71] Basis - The coking coal spot has a premium over the 01 contract, and basis data are presented [74][75][76]

Investment Rating - The report maintains a "Positive" outlook on the non-bank financial sector [1] Core Views - The report highlights a continuation of strong growth in the brokerage sector, with a significant increase in net profits expected for the first nine months of 2025. Key metrics include a 61% year-on-year increase in new A-share accounts and a 203% increase in average daily stock trading volume in September 2025 [2][5] - The brokerage sector is currently undervalued, with a price-to-book (PB) ratio of 1.48, placing it in the 47.8th percentile over the past decade [2] - The report notes a favorable market environment supporting continued high growth in brokerage performance, with specific recommendations for leading firms and those with strong international business capabilities [2][7] Summary by Sections Market Review - The Shanghai Composite Index rose by 1.47% during the period from September 29 to October 10, 2025, while the non-bank index increased by 3.18%. The brokerage, insurance, and diversified financial sectors reported gains of 4.42%, 0.89%, and 0.52%, respectively [5][6] Non-Bank Sector Insights - The report indicates that the insurance sector is benefiting from the implementation of a "de-involution" policy framework for non-auto insurance, which is expected to improve underwriting profitability for leading firms [2][16] - Specific investment recommendations include firms that are expected to benefit from improved competitive dynamics and those with strong earnings elasticity [2][7] Key Data Tracking - As of October 10, 2025, the average daily trading volume in the stock market was 26,034.09 billion yuan, reflecting an 18.99% increase from the previous period [14][32] - The report also tracks significant metrics such as the balance of margin financing and securities lending, which stood at 24,455.47 billion yuan as of October 9, 2025, marking a 31.2% increase from the end of 2024 [14][39]

Group 1 - China's GDP growth in the first half of the year exceeded expectations at over 5.3%, indicating strong long-term growth potential despite short-term structural disparities in the economy [1] - The real estate sector remains a significant drag on domestic demand, as it holds a high share in residents' wealth allocation, impacting consumption sources [1] - The article emphasizes the need to stabilize housing prices and explores variables that could indicate when housing prices are stabilized [1] Group 2 - The concepts of rental yield and price-to-rent ratio are introduced, with rental yield measuring the annual rental income relative to the property's sale price [2] - A common belief is that if rental yields exceed government bond rates, properties become more attractive, but historical examples from the U.S. and Japan show this logic may not hold true [2][5] - The article argues that housing is akin to "credit bonds," where price fluctuations affect perceived value, unlike stable government bonds [5] Group 3 - The return on investment in real estate comes from both rental income and capital gains, with expectations of price increases diminishing the importance of rental yields [6] - When housing price expectations are low, rental yields must be significantly higher to compensate for potential price declines and associated costs [6] - The article draws parallels between real estate and stock market behaviors, noting that both markets react similarly to investor expectations [7] Group 4 - The analysis of 13 economies reveals that once housing prices enter a downward cycle, valuations tend to revert to historical lows, similar to stock market trends [7] - Stabilizing housing prices requires more than just increasing rental yields; it necessitates managing price expectations, which are influenced by macroeconomic inflation expectations [7][8] - Recent macroeconomic policies in China have focused on boosting expectations and inflation, which could positively impact housing price stability in the future [8]

Core Viewpoint - The brokerage firms in China have significantly increased their bond issuance this year, with a total of 1.26 trillion yuan, marking a year-on-year growth of 75.42% [1][2][3] Group 1: Bond Issuance Details - As of October 10, 2023, several brokerages, including China International Capital Corporation (CICC), Industrial Securities, and Zhongyuan Securities, have announced progress in bond approvals or listings [1][2] - CICC plans to issue up to 10 billion yuan in corporate bonds, while Industrial Securities has received approval for a public issuance of up to 20 billion yuan [1][2] - China Galaxy Securities leads the bond issuance with 107.9 billion yuan, followed by Huatai Securities with 98.1 billion yuan, and Guotai Junan with 87 billion yuan [2] Group 2: Factors Driving Bond Issuance - The increase in bond issuance is attributed to a recovering market, rising capital-intensive businesses like margin trading and derivatives, and a slowdown in equity financing [3][4] - Company bonds have become the preferred method for brokerages, reflecting their long-term funding needs and the advantages of lower costs compared to equity financing [3][4] - Regulatory changes have also influenced the shift towards bond financing, as the pace of equity financing has slowed down due to new regulations promoting capital-efficient and high-quality development [4]

Core Viewpoint - The bond issuance by securities firms in China has surged significantly in 2023, reflecting a strong demand for capital amid a recovering market environment [1][3]. Group 1: Bond Issuance Data - As of October 10, 2023, the total bond issuance by securities firms in China reached 1.26 trillion yuan, representing a year-on-year increase of 75.42% [1][3]. - China Galaxy Securities leads the market with a bond issuance of 107.9 billion yuan, followed by Huatai Securities at 98.1 billion yuan and Guotai Junan at 87 billion yuan [3]. Group 2: Factors Driving Bond Issuance - The increase in bond issuance is attributed to a recovering market, heightened capital needs for margin trading and derivatives, and a slowdown in equity financing [3][4]. - Company bonds have become the preferred method for financing, with a notable shift away from short-term financing bonds and perpetual subordinated bonds [3]. Group 3: Purpose of Bond Financing - The primary uses of the funds raised through bond issuance include repaying maturing debts, supplementing working capital, and supporting daily operations and business development [4]. - The low interest rate environment has made bond financing more attractive compared to equity financing, allowing firms to manage financial expenditures effectively [4]. Group 4: Regulatory Environment - The regulatory environment has also influenced the shift towards bond financing, as the pace of equity financing through private placements and rights issues has slowed down [4].

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - After the "Jiusan" consensus was fulfilled, the market entered a moderately shrinking rotation phase, with broad - based index gains narrowing. The basis showed significant two - way fluctuations, weakly correlated with daily index movements, and the divergence at the 1 - minute level increased, indicating weak and disordered risk sentiment in the futures market. The changes in neutral and CTA strategy products also reflected this. In the short term, the two - way basis fluctuations may continue, and in the long run, if the policy of reducing volatility is implemented, the central level of stock index futures discounts may narrow [5][15]. 3. Summary According to the Directory 3.1 Recent Basis Review - Market Conditions: After the "Jiusan" consensus was fulfilled, the market entered a moderately shrinking rotation phase. The ChiNext and STAR Market indices led the gains in September, while the gains of other indices narrowed, and the small - cap index declined. Domestic policies were relatively quiet, with a focus on "anti - involution" and potential future volatility - reduction policies. Overseas, the Fed cut interest rates by 25bp, and the A - share market reacted calmly to the Sino - US Madrid talks. Daily trading volume gradually decreased to around 2.2 trillion yuan [6]. - Basis Changes: At the beginning of September, the basis of each variety weakened with the index decline. Subsequently, it fluctuated up and down during the index recovery. By the end of the month, the basis of IF, IC, and IM strengthened. Overall, the basis of IH and IF decreased compared to the end of August, while that of IC and IM increased. As of September 30, the annualized basis rates of the four varieties' quarterly contracts had recovered to around the 20th percentile in the past three years. The daily - level basis changes were weakly correlated with index changes, and there was significant divergence at the 1 - minute level, indicating weak risk appetite [9]. - Product - end Performance: Index - related product scale was stable with a slight decline, and the number of newly issued public - offering index - enhanced products reached a new monthly high. The net value curve of neutral strategies flattened in the past two months, with a median annual return of around 5.5%, and both long and short positions decreased in September. The CTA strategy's leverage ratio for stock indices remained stable, but the net long position fluctuated significantly, reflecting disordered market sentiment [14]. 3.2 Performance Review of Long - Position Rollover - The annualized excess returns of the long - position rollover strategy for IF, IH, IC, and IM in the past 250 trading days were - 2.7%, 0.2%, 1.2%, and - 3.0% respectively. The benchmark portfolio was set as a weighted combination based on the previous trading day's contract positions, without considering transaction costs, and the trading price was the TWAP price in the first half - hour of trading [5][22]. 3.3 Performance Review of Short - Position Rollover - The annualized excess returns of the short - position rollover strategy for IF, IH, IC, and IM in the past 250 trading days were - 0.5%, - 0.3%, 2.2%, and 0.6% respectively [5][25].

Core Viewpoint - The company, Shibu Testing (301228.SZ), reported a decline in revenue and continued net losses for the first half of 2025, indicating ongoing financial challenges [1][2]. Financial Performance - For the first half of 2025, the company achieved operating revenue of 167.20 million yuan, a year-on-year decrease of 15.97% compared to 198.98 million yuan in the same period last year [2]. - The net profit attributable to shareholders was -26.98 million yuan, slightly worsening from -26.33 million yuan in the previous year, reflecting a decrease of 2.45% [2]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -28.66 million yuan, compared to -27.35 million yuan in the same period last year, marking a decline of 4.79% [2]. - The net cash flow from operating activities was -14.55 million yuan, a significant drop from -9.99 million yuan in the previous year, representing a decrease of 45.65% [2]. Historical Financial Data - From 2022 to 2024, the company's operating revenue was 351.47 million yuan, 373.83 million yuan, and 442.11 million yuan, respectively, showing a growth trend [3]. - The net profit attributable to shareholders for the same years was -17.96 million yuan, -93.54 million yuan, and -65.79 million yuan, indicating a gradual improvement in losses [3]. - The net profit after deducting non-recurring gains and losses for the same years was -31.35 million yuan, -97.71 million yuan, and -67.02 million yuan, also showing a trend of reduced losses [3]. - The net cash flow from operating activities for these years was 782.06 thousand yuan, -1.36 million yuan, and 24.35 million yuan, indicating a significant recovery in cash flow in 2024 [3]. Initial Public Offering (IPO) Details - Shibu Testing was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 28, 2022, with a public offering of 30 million shares, accounting for 25% of the total share capital post-issue, at a price of 20.08 yuan per share [4]. - The total amount raised from the IPO was 602.40 million yuan, with a net amount of 526.33 million yuan after deducting issuance costs, exceeding the original plan by 124.23 million yuan [4]. - The funds raised are intended for the construction of a new laboratory project, the establishment of a research and development information center, and to supplement working capital [4].

Core Insights - AMD has signed a 6GW computing power chip cooperation agreement with OpenAI, which is expected to accelerate the ROCm ecosystem development [1] - The Haiguang DTK software stack is fully compatible with the ROCm ecosystem, potentially reducing the adaptation costs for large models in China [2] - Industrial and commercial banks, along with China Unicom, are procuring Haiguang chips worth several billion yuan, indicating a rapid penetration of Haiguang chips in the domestic market [3] Group 1 - AMD and OpenAI's agreement includes the deployment of a total of 6GW of AMD GPU computing power, starting with 1GW based on the MI450 series GPU in the second half of 2026 [1] - The collaboration is seen as a response to the significant gap in AI computing power supply and aims to enhance the synergy between AMD and OpenAI in both hardware and software [1] - ROCm 7 is expected to be available by Q3 2025, offering over 3.5 times the inference capability and three times the training capability compared to ROCm 6 [1] Group 2 - The Haiguang DCU features a complete software stack, including DTK, development toolchain, and model repository, which supports mainstream deep learning frameworks like TensorFlow and Pytorch [2] - This compatibility is anticipated to effectively lower the costs associated with adapting large models domestically [2] Group 3 - Industrial and Commercial Bank of China has announced a procurement project for Haiguang chip servers, with a potential total procurement amount reaching 3 billion yuan [3] - China Unicom's procurement project for Haiguang servers has a budget of 2.782 billion yuan, indicating strong demand for domestic chip solutions [3] - The financial and telecommunications sectors are expected to lead the way in achieving comprehensive domestic production, thereby accelerating the penetration of Haiguang chips [3]

Core Points - The Shanghai Composite Index is at 3927.63 points, slightly down by 0.16%, with a total trading volume of 1.2446 trillion yuan [1] - A total of 181 A-shares have surpassed the half-year line, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - Li Min Co., Ltd. (002734) has a deviation rate of 4.31% with a price increase of 6.27% [1] - Yuanda Environmental Protection (600292) shows a deviation rate of 3.35% and a price increase of 3.93% [1] - Oriental Carbon (920175) has a deviation rate of 3.28% with an 8.17% price increase [1] Trading Activity - The total trading volume for A-shares today is reported at 1.2446 trillion yuan [1] - The stocks with the smallest deviation rates include Lian Ke Technology, Lingkang Pharmaceutical, and Publishing Media, which have just crossed the half-year line [1] Deviation Rate Rankings - The top stocks with the highest deviation rates include: - Li Min Co., Ltd. (002734) at 4.31% - Yuanda Environmental Protection (600292) at 3.35% - Oriental Carbon (920175) at 3.28% [1] - Other notable stocks with significant price increases and deviation rates include: - Han Commercial Group (600774) at 3.19% - Rui Pu Biological (300119) at 2.99% [1]

Core Insights - The report from Guotai Junan highlights that small nucleic acid drugs, particularly siRNA, are transitioning from rare diseases to common diseases due to technological advancements and product approvals [1][2] Group 1: Technological Advancements - The siRNA drugs are characterized by strong target expansion capabilities, extensive research adaptability, long-lasting effects, and low resistance [1] - Since 2016, the upgrade of the GalNac delivery system and the application of complete modification have propelled siRNA drugs into a rapid development phase, validating their value in rare diseases and now moving towards common diseases [1][3] Group 2: Market Dynamics - The market for small nucleic acid drugs is experiencing active business development (BD) transactions, with Chinese companies expected to shine due to their engineering advantages, particularly in chemical synthesis [2] - The ongoing patent cliff faced by many pharmaceutical companies necessitates new products to mitigate potential risks, making the acquisition of pipelines from companies specializing in small nucleic acid technology a quick solution [2] Group 3: Industry Characteristics - The commercialization of siRNA drugs is focused on common diseases with clear biological mechanisms, where early movers can achieve better commercial returns and collaboration opportunities [3] - The efficiency and specificity of the GalNac delivery system, along with potential patent breakthroughs, indicate high competition in diseases with clear pathogenic genes or mechanisms [3] Group 4: Domestic Companies - Listed companies in the small nucleic acid drug sector include Yuyuan Pharmaceutical, Hengrui Medicine, CSPC Pharmaceutical Group, Junshi Biosciences, Frontier Biotechnologies, Fuyuan Pharmaceutical, Chengdu Xian Dao, and Shengnuo Pharmaceutical [4] - Unlisted companies include Bowang Pharmaceutical, Rebo Biotech, Jingyin Pharmaceutical, Shengyin Biotech, Dairui Biotech, and Weia Zhen Biotech [4]